What is the clinical evidence from this study?

Study design: Other. Population: Hypertriglyceridemia (n=20). Intervention: Fenofibrate vs. Baseline. Primary outcome: Triglyceride (TG) levels (-58.4%, p=<0.001).

January 1, 2004Journal of Atherosclerosis and ThrombosisOpen Access

Fenofibrate Effectively Reduces Remnants, and Small Dense LDL, and Increases HDL Particle Number in Hypertriglyceridemic Men A Nuclear Magnetic Resonance Study

Q: What are the key findings of this study?

Fenofibrate significantly reduced triglycerides by 58.4% and increased HDL-C by 18.2%, while improving atherogenic dyslipidemia by reducing remnants and small LDL particles.

View Full Paper

Ask AI

Bookmark

Key result

Fenofibrate significantly reduced triglycerides by 58.4% and increased HDL-C by 18.2%, while improving atherogenic dyslipidemia by reducing remnants and small LDL particles.

Why the study?

Does fenofibrate improve lipoprotein subfraction profiles and inflammation markers in hypertriglyceridemic men?

Population

20 hypertriglyceridemic men

Design

Cohort

Follow-up

8 weeks

Authors

KIKatsunori IkewakiThe Jikei University Hospital JTJunichiro TohyamaUniversity of Pennsylvania YNYoshinobu NakataJikei University School of Medicine

Discussion

Member takes

Implication

Fenofibrate was associated with improved lipoprotein subfractions; leaves open whether these shifts improve outcomes in hypertriglyceridemia.

Structured PICO

Does fenofibrate improve lipoprotein subfraction profiles and inflammation markers in hypertriglyceridemic men?

Population

20 hypertriglyceridemic men aged 30 to 80 years with fasting triglycerides ≥ 150 mg/dl, treated with fenofibrate for 8 weeks.

Intervention

Fenofibrate 200 mg daily for 8 weeks

Outcome

Lipoprotein subfraction profile measured by nuclear magnetic resonance (NMR) spectroscopy and inflammation markers (CRP, IL-6, and MCP-1)surrogate

Main Result

Effect estimate: -58.4%

Absolute Event Rate: 200% vs 480%

p-value: p=<0.001

Fenofibrate effectively improves atherogenic dyslipidemia by reducing remnants and small LDL, increasing HDL particles, and reducing inflammation in hypertriglyceridemic men.

Limitations

Lacked a control group for comparison
Study subjects were exclusively men, limiting generalizability to women
Relatively short treatment duration of 8 weeks
Small sample size

Cite This Study

Ikewaki et al. (2004) studied Hypertriglyceridemia (n=20). Fenofibrate vs. Baseline was evaluated on Triglyceride (TG) levels (-58.4%, p=<0.001). Fenofibrate significantly reduced triglycerides by 58.4% and increased HDL-C by 18.2%, while improving atherogenic dyslipidemia by reducing remnants and small LDL particles.

synapsesocial.com/papers/6a5e75fb142b9bcc06fda907 https://doi.org/10.5551/jat.11.278

View Full Paper

Ask AI

Bookmark

Implication

Fenofibrate was associated with improved lipoprotein subfractions; leaves open whether these shifts improve outcomes in hypertriglyceridemia.

Fenofibrate Effectively Reduces Remnants, and Small Dense LDL, and Increases HDL Particle Number in Hypertriglyceridemic Men A Nuclear Magnetic Resonance Study

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Fenofibrate Effectively Reduces Remnants, and Small Dense LDL, and Increases HDL Particle Number in Hypertriglyceridemic Men A Nuclear Magnetic Resonance Study

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Also Consider

Also Consider